Press coverage about Pulmatrix (NASDAQ:PULM) has trended positive recently, according to AlphaOne Sentiment Analysis. AlphaOne, a service of Accern, identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pulmatrix earned a coverage optimism score of 0.26 on AlphaOne’s scale. AlphaOne also gave media stories about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Alpha One Sentiment Analysis’s scoring:
- Pulmatrix’s Unique Inhaled Drug Candidate Has “Blockbuster” Potential, Says CFO Bill Duke (money.ca)
- Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN… (finanznachrichten.de)
- Pulmatrix Inc : Pulmatrix’s Unique Inhaled Drug Candidate Has “Blockbuster” Potential, Says CFO Bill Duke (4-traders.com)
- Today’s Research Reports on Biotech Stocks to Watch: Pulmatrix and Puma Biotechnology (finance.yahoo.com)
Pulmatrix (NASDAQ:PULM) opened at 2.76 on Friday. The company’s market cap is $52.78 million. Pulmatrix has a 52-week low of $0.50 and a 52-week high of $6.98. The stock’s 50 day moving average is $2.86 and its 200 day moving average is $2.26.
Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings data on Friday, May 5th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 91.67% and a negative net margin of 2,273.08%. Equities research analysts forecast that Pulmatrix will post ($4.13) earnings per share for the current year.
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc and related companies with MarketBeat.com's FREE daily email newsletter.